Author

Gabriela M. Wright

Moffitt Cancer CenterORCID 0000-0002-3524-6831Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Eric B. HauraiD· 2 shared John M. KoomeniD· 2 shared Aileen Y. AlontagaiD· 1 shared Andriy MarusykiD· 1 shared Ashley LuiiD· 1 shared Bin FangiD· 1 shared Bina DesaiiD· 1 shared Christina L. Carr· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Eric B. HauraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 18, 2026

Ex Vivo Culture of Patient-Derived Primary, Metastatic, and Post-Mortem Lung Cancer Reveals Targetable States of EMT and Metabolic Plasticity

Suehelay Acevedo‐Acevedo, Hayley D. Ackerman, Vanessa Y. Rubio…·Elsa Renee Flores

The paper develops microtumor models from lung cancer samples to study EMT and metabolic changes, identifying fatty acid synthesis as a targetable vulnerability.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyScience SignalingPeer-reviewedDec 23, 2025

Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK-driven lung cancer via concurrent integrin and MET signaling

Qianqian Hu, Lily L. Remsing Rix, Bina Desai…·Uwe Rix

This study identifies that CAFs confer ALK inhibitor resistance in EML4-ALK-driven lung cancer through both MET and integrin signaling pathways, and shows that targeting both pathways improves treatment efficacy.

6 citations

mouseproteomics

𝕏 PostBluesky